Notes / Company

Panacea Biotec Ltd.

PANACEABIO BSE 531349 ISIN INE922B01023 Pharmaceuticals

Fundamentals

Market cap: ₹3,413 cr
ROE: 0.00%
Debt / equity: 0.03
52-week range: 292.40 — 647.00

Research on Tijori Finance

Company snapshot

Panacea Biotec Ltd.

Pharmaceuticals

₹3,359 cr

Latest quarter · Mar 2026

Sales₹167 cr

Net profit−₹1 cr

Op. margin+1.5%

EPS₹0.08

Strength & growth

Debt / equity0.03×

Current ratio1.49×

Sales CAGR−0.1%

The timeline — 3 notes on Panacea Biotec Ltd.

July 2026

16 Jul 26 · 3:22 PM IST Brief

Brief · Small cap

Panacea Biotec gets HC stay on labour award recoveries

The company has now appealed all 4 tribunal awards. The High Court's interim order prevents coercive action on the first 3, reducing immediate enforcement risk.

June 2026

08 Jun 26 · 6:24 PM IST Brief

Brief · M&A · Small cap

Panacea Biotec joins EU consortium to test dengue vaccine in Africa

The €11.1 million project will run Phase I/III trials of the single-dose DengiAll vaccine in sub-Saharan Africa. The grant goes to the consortium, not Panacea.

May 2026

31 May 26 · 1:11 AM IST Brief

Brief · Earnings · Small cap

Panacea Biotec reports widening losses as auditors flag stability

The company reported a standalone net loss of ₹2,988 lakh for FY26, double the prior year's loss, prompting an auditor qualification.

Verify on exchange BSE filings for PANACEABIO NSE filings for PANACEABIO Tijori Finance company page